ShorDiCell® patented approach
ShorDiCell® – a patented stem cell treatment approach
Biopro Stem Technology has developed an approach to stem cell treatment called ShorDiCell®, which enables to get a high purity cell preparation, containing 99.5-99.8% of stem cells.
It’s being actively used in clinical practice, as well as aesthetic medicine.
Due to such high levels of stem cell saturation, we are able to achieve better treatment results with this, compared to preparations using stem cells obtained from bone marrow or cord blood.
Our patented approach has been effectively used in the treatment of the following conditions:
- Disorders involving blood vessels of the extremities, such as obliterating endarteritis, diabetic microangiopathy, arteriosclerosis obliterans
- Cardiovascular disorders, such as atherosclerosis, ischemic heart disease, myocardial infarction, hypertension, thrombophlebitis
- Autoimmune disorders, such as psoriasis, systemic lupus erythematosus, hepatitis, thyroiditis, glomerulonephritis, prostatitis, scleroderma
- Conditions involving cartilage (arthritis, arthrosis, nonunion)
- Crohn’s disease, nonspecific ulcerative colitis
- Diabetes I and II types
- Liver disorders, including cirrhosis
- Acute renal failure
Typical treatment plan involving mesenchymal stem cells (using patented ShorDiCell® approach):
Stage 1 – either blood or adipose tissue (depending on the physician’s orders) is extracted from the patient. Blood is usually extracted from a vein, about 10 ml of it. If it’s adipose tissue, then it’s around 1-3 ml. Adipose tissue extraction usually lasts about 30 minutes and is performed under local anaesthesia.
Stage 2 – patient’s autologous stem cells are then grown in our lab until they reach an effective therapeutic dose.
Stage 3 – patient is invited to our clinic, where they receive an intravenous injection of their own (autologous) stem cells. This usually takes 10 to 15 minutes. The basic injection course consists of 2 or 3 injections, with an interval of a week between each.
Biopro Stem Technology’s lab is fully compliant with GCP (Good clinical practice) and GLP (Good laboratory practice) standards.
A sample of patient’s biomaterial is delivered to the lab in compliance with GCP protocols.
The material is filtered out to leave only stem cells. What remains is then tested for chromosomal defects, so that only healthy and robust cells are used for growth and treatment.
Cells that pass those tests are then selected for further growth until an effective therapeutic dose is achieved.
Patients should abstain from the procedure, if they experience acute symptoms of an infection, high fever in particular.